Literature DB >> 23578105

Characterization of genetic lesions in rhabdomyosarcoma using a high-density single nucleotide polymorphism array.

Riki Nishimura1, Junko Takita, Aiko Sato-Otsubo, Motohiro Kato, Katsuyoshi Koh, Ryoji Hanada, Yukichi Tanaka, Keisuke Kato, Daichi Maeda, Masashi Fukayama, Masashi Sanada, Yasuhide Hayashi, Seishi Ogawa.   

Abstract

Rhabdomyosarcoma (RMS) is a common solid tumor in childhood divided into two histological subtypes, embryonal (ERMS) and alveolar (ARMS). The ARMS subtype shows aggressive clinical behavior with poor prognosis, while the ERMS subtype has a more favorable outcome. Because of the rarity, diagnostic diversity and heterogeneity of this tumor, its etiology remains to be completely elucidated. Thus, to identify genetic alterations associated with RMS development, we performed single nucleotide polymorphism array analyses of 55 RMS samples including eight RMS-derived cell lines. The ERMS subtype was characterized by hyperploidy, significantly associated with gains of chromosomes 2, 8 and 12, whereas the majority of ARMS cases exhibited near-diploid copy number profiles. Loss of heterozygosity of 15q was detected in 45.5% of ARMS that had been unrecognized in RMS to date. Novel amplifications were also detected, including IRS2 locus in two fusion-positive tumors, and KRAS or NRAS loci in three ERMS cases. Of note, gain of 13q was significantly associated with good patient outcome in ERMS. We also identified possible application of an ALK inhibitor to RMS, as ALK amplification and frequent expression of ALK were detected in our RMS cohort. These findings enhance our understanding of the genetic mechanisms underlying RMS pathogenesis and support further studies for therapeutic development of RMS.
© 2013 Japanese Cancer Association.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23578105      PMCID: PMC7657110          DOI: 10.1111/cas.12173

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  49 in total

1.  Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer.

Authors:  Sandra Misale; Rona Yaeger; Sebastijan Hobor; Elisa Scala; Manickam Janakiraman; David Liska; Emanuele Valtorta; Roberta Schiavo; Michela Buscarino; Giulia Siravegna; Katia Bencardino; Andrea Cercek; Chin-Tung Chen; Silvio Veronese; Carlo Zanon; Andrea Sartore-Bianchi; Marcello Gambacorta; Margherita Gallicchio; Efsevia Vakiani; Valentina Boscaro; Enzo Medico; Martin Weiser; Salvatore Siena; Federica Di Nicolantonio; David Solit; Alberto Bardelli
Journal:  Nature       Date:  2012-06-28       Impact factor: 49.962

2.  Genomic and clinical analysis of fusion gene amplification in rhabdomyosarcoma: a report from the Children's Oncology Group.

Authors:  Fenghai Duan; Lynette M Smith; Donna M Gustafson; Chune Zhang; Mandy J Dunlevy; Julie M Gastier-Foster; Frederic G Barr
Journal:  Genes Chromosomes Cancer       Date:  2012-03-23       Impact factor: 5.006

3.  Anaplastic lymphoma kinase aberrations in rhabdomyosarcoma: clinical and prognostic implications.

Authors:  J Carlijn van Gaal; Uta E Flucke; Melissa H S Roeffen; Eveline S J M de Bont; Stefan Sleijfer; Annelies M C Mavinkurve-Groothuis; Albert J H Suurmeijer; Winette T A van der Graaf; Yvonne M H Versleijen-Jonkers
Journal:  J Clin Oncol       Date:  2011-12-19       Impact factor: 44.544

4.  Loss of heterozygosity analysis defines a 3-cM region of 15q commonly deleted in human malignant mesothelioma.

Authors:  A De Rienzo; B R Balsara; S Apostolou; S C Jhanwar; J R Testa
Journal:  Oncogene       Date:  2001-09-27       Impact factor: 9.867

5.  Genomic and clinical analysis of amplification of the 13q31 chromosomal region in alveolar rhabdomyosarcoma: a report from the Children's Oncology Group.

Authors:  Jennifer L Reichek; Fenghai Duan; Lynette M Smith; Donna M Gustafson; Roddy S O'Connor; Chune Zhang; Mandy J Dunlevy; Julie M Gastier-Foster; Frederic G Barr
Journal:  Clin Cancer Res       Date:  2011-01-10       Impact factor: 12.531

6.  Genome-wide detection of allelic imbalance using human SNPs and high-density DNA arrays.

Authors:  R Mei; P C Galipeau; C Prass; A Berno; G Ghandour; N Patil; R K Wolff; M S Chee; B J Reid; D J Lockhart
Journal:  Genome Res       Date:  2000-08       Impact factor: 9.043

7.  A robust algorithm for copy number detection using high-density oligonucleotide single nucleotide polymorphism genotyping arrays.

Authors:  Yasuhito Nannya; Masashi Sanada; Kumi Nakazaki; Noriko Hosoya; Lili Wang; Akira Hangaishi; Mineo Kurokawa; Shigeru Chiba; Dione K Bailey; Giulia C Kennedy; Seishi Ogawa
Journal:  Cancer Res       Date:  2005-07-15       Impact factor: 12.701

8.  Frequency and clinicopathologic correlates of KRAS amplification in non-small cell lung carcinoma.

Authors:  Patrick L Wagner; Ann-Cathrin Stiedl; Theresia Wilbertz; Karen Petersen; Veit Scheble; Roopika Menon; Markus Reischl; Ralf Mikut; Mark A Rubin; Falko Fend; Holger Moch; Alex Soltermann; Walter Weder; Nasser K Altorki; Sven Perner
Journal:  Lung Cancer       Date:  2011-04-08       Impact factor: 5.705

9.  Highly sensitive method for genomewide detection of allelic composition in nonpaired, primary tumor specimens by use of affymetrix single-nucleotide-polymorphism genotyping microarrays.

Authors:  Go Yamamoto; Yasuhito Nannya; Motohiro Kato; Masashi Sanada; Ross L Levine; Norihiko Kawamata; Akira Hangaishi; Mineo Kurokawa; Shigeru Chiba; D Gary Gilliland; H Phillip Koeffler; Seishi Ogawa
Journal:  Am J Hum Genet       Date:  2007-06-05       Impact factor: 11.025

10.  A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets.

Authors:  Niantao Deng; Liang Kee Goh; Hannah Wang; Kakoli Das; Jiong Tao; Iain Beehuat Tan; Shenli Zhang; Minghui Lee; Jeanie Wu; Kiat Hon Lim; Zhengdeng Lei; Glenn Goh; Qing-Yan Lim; Angie Lay-Keng Tan; Dianne Yu Sin Poh; Sudep Riahi; Sandra Bell; Michael M Shi; Ronald Linnartz; Feng Zhu; Khay Guan Yeoh; Han Chong Toh; Wei Peng Yong; Hyun Cheol Cheong; Sun Young Rha; Alex Boussioutas; Heike Grabsch; Steve Rozen; Patrick Tan
Journal:  Gut       Date:  2012-02-07       Impact factor: 23.059

View more
  18 in total

1.  GPC5, a novel epigenetically silenced tumor suppressor, inhibits tumor growth by suppressing Wnt/β-catenin signaling in lung adenocarcinoma.

Authors:  S Yuan; Z Yu; Q Liu; M Zhang; Y Xiang; N Wu; L Wu; Z Hu; B Xu; T Cai; X Ma; Y Zhang; C Liao; L Wang; P Yang; L Bai; Y Li
Journal:  Oncogene       Date:  2016-05-09       Impact factor: 9.867

Review 2.  The Role of Glypicans in Cancer Progression and Therapy.

Authors:  Nan Li; Madeline R Spetz; Mitchell Ho
Journal:  J Histochem Cytochem       Date:  2020-07-06       Impact factor: 2.479

3.  Primary cardiac rhabdomyosarcoma developed after receiving radiotherapy for left breast cancer 18 years prior.

Authors:  Satomi Suehiro; Morihiro Matsuda; Taizo Hirata; Daiki Taniyama; Kazuya Kuraoka; Tai-Ichi Takasaki; Takatsugu Segawa; Toshiharu Oka; Ritsu Tamura; Hiroshi Sugino
Journal:  J Cardiol Cases       Date:  2017-03-07

Review 4.  Glypicans as Cancer Therapeutic Targets.

Authors:  Nan Li; Wei Gao; Yi-Fan Zhang; Mitchell Ho
Journal:  Trends Cancer       Date:  2018-09-28

Review 5.  Soft Tissue Special Issue: Skeletal Muscle Tumors: A Clinicopathological Review.

Authors:  Kenichi Kohashi; Izumi Kinoshita; Yoshinao Oda
Journal:  Head Neck Pathol       Date:  2020-01-16

6.  Characterization of genetic lesions in rhabdomyosarcoma using a high-density single nucleotide polymorphism array.

Authors:  Riki Nishimura; Junko Takita; Aiko Sato-Otsubo; Motohiro Kato; Katsuyoshi Koh; Ryoji Hanada; Yukichi Tanaka; Keisuke Kato; Daichi Maeda; Masashi Fukayama; Masashi Sanada; Yasuhide Hayashi; Seishi Ogawa
Journal:  Cancer Sci       Date:  2013-05-23       Impact factor: 6.716

7.  Integrated genetic and epigenetic analysis defines novel molecular subgroups in rhabdomyosarcoma.

Authors:  Masafumi Seki; Riki Nishimura; Kenichi Yoshida; Teppei Shimamura; Yuichi Shiraishi; Yusuke Sato; Motohiro Kato; Kenichi Chiba; Hiroko Tanaka; Noriko Hoshino; Genta Nagae; Yusuke Shiozawa; Yusuke Okuno; Hajime Hosoi; Yukichi Tanaka; Hajime Okita; Mitsuru Miyachi; Ryota Souzaki; Tomoaki Taguchi; Katsuyoshi Koh; Ryoji Hanada; Keisuke Kato; Yuko Nomura; Masaharu Akiyama; Akira Oka; Takashi Igarashi; Satoru Miyano; Hiroyuki Aburatani; Yasuhide Hayashi; Seishi Ogawa; Junko Takita
Journal:  Nat Commun       Date:  2015-07-03       Impact factor: 14.919

Review 8.  Asparaginase treatment side-effects may be due to genes with homopolymeric Asn codons (Review-Hypothesis).

Authors:  Julian Banerji
Journal:  Int J Mol Med       Date:  2015-07-15       Impact factor: 4.101

9.  Understanding the Interplay between Expression, Mutation and Activity of ALK Receptor in Rhabdomyosarcoma Cells for Clinical Application of Small-Molecule Inhibitors.

Authors:  Marica Peron; Federica Lovisa; Elena Poli; Giuseppe Basso; Paolo Bonvini
Journal:  PLoS One       Date:  2015-07-06       Impact factor: 3.240

10.  GPC5 suppresses lung cancer progression and metastasis via intracellular CTDSP1/AhR/ARNT signaling axis and extracellular exosome secretion.

Authors:  Xin Yang; Yan Chen; You Zhou; Chen Wu; Qing Li; Jun Wu; Wen Wei Hu; Wei Qing Zhao; Wei Wei; Chang Ping Wu; Jing Ting Jiang; Mei Ji
Journal:  Oncogene       Date:  2021-06-02       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.